Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: The RELIEF trial

医学 内科学 自发性细菌性腹膜炎 胃肠病学 肝性脑病 透析 肝硬化 人口 优势比 肌酐 肝病 置信区间 外科 环境卫生
作者
Rafael Bañares,Frederik Nevens,Fin Stolze Larsen,Rajiv Jalan,Agustín Albillos,Matthias M. Dollinger,Faouzi Saliba,Tilman Sauerbruch,Sebastian Klammt,Johann Ockenga,Albert Rodrigo Parés,Julia Alexis Wendon,Tanja Brünnler,Ludwig Kramer,Philippe Mathurin,Manuel de la Mata,Antonio Gasbarrini,Beat Müllhaupt,Alexander P. Wilmer,Wim Laleman
出处
期刊:Hepatology [Lippincott Williams & Wilkins]
卷期号:57 (3): 1153-1162 被引量:612
标识
DOI:10.1002/hep.26185
摘要

UNLABELLED: Acute-on-chronic liver failure (ACLF) is a frequent cause of death in cirrhosis. Albumin dialysis with the molecular adsorbent recirculating system (MARS) decreases retained substances and improves hemodynamics and hepatic encephalopathy (HE). However, its survival impact is unknown. In all, 189 patients with ACLF were randomized either to MARS (n=95) or to standard therapy (SMT) (n=94). Ten patients (five per group) were excluded due to protocol violations. In addition, 23 patients (MARS: 19; SMT: 4) were excluded from per-protocol (PP) analysis (PP population n=156). Up to 10 6-8-hour MARS sessions were scheduled. The main endpoint was 28-day ITT and PP survival. There were no significant differences at inclusion, although the proportion of patients with Model for Endstage Liver Disease (MELD) score over 20 points and with spontaneous bacterial peritonitis (SBP) as a precipitating event was almost significantly greater in the MARS group. The 28-day survival was similar in the two groups in the ITT and PP populations (60.7% versus 58.9%; 60% versus 59.2% respectively). After adjusting for confounders, a significant beneficial effect of MARS on survival was not observed (odds ratio [OR]: 0.87, 95% confidence interval [CI] 0.44-1.72). MELD score and HE at admission and the increase in serum bilirubin at day 4 were independent predictors of death. At day 4, a greater decrease in serum creatinine (P=0.02) and bilirubin (P=0.001) and a more frequent improvement in HE (from grade II-IV to grade 0-I; 62.5% versus 38.2%; P=0.07) was observed in the MARS group. Severe adverse events were similar. CONCLUSION: At scheduled doses, a beneficial effect on survival of MARS therapy in patients with ACLF could not be demonstrated. However, MARS has an acceptable safety profile, has significant dialysis effect, and nonsignificantly improves severe HE.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
elizabeth339发布了新的文献求助10
2秒前
2秒前
bkagyin的应助被辉煌采纳,获得10
2秒前
Frichare完成签到,获得积分10
2秒前
3秒前
firsty完成签到,获得积分10
3秒前
taku完成签到 ,获得积分0
3秒前
结实的秋天完成签到,获得积分20
4秒前
Eyrie2001完成签到,获得积分10
4秒前
嘟嘟发布了新的文献求助10
5秒前
无花果的应助被要减肥含灵采纳,获得10
5秒前
Rastro发布了新的文献求助30
7秒前
hjy发布了新的文献求助10
8秒前
无限玉米完成签到,获得积分10
8秒前
迷人雪珊完成签到 ,获得积分10
9秒前
fantasy的应助被Pan采纳,获得10
10秒前
认真芷容发布了新的文献求助10
11秒前
12秒前
吴丹完成签到,获得积分10
12秒前
星辰大海的应助被易博采纳,获得10
12秒前
科研通AI6.4的应助被zyy采纳,获得10
13秒前
搜集达人的应助被白华苍松采纳,获得10
13秒前
13秒前
12完成签到,获得积分10
14秒前
14秒前
JAY完成签到,获得积分10
14秒前
老汉憨憨完成签到,获得积分20
14秒前
Jason发布了新的文献求助10
14秒前
赘婿的应助被王士钰采纳,获得10
14秒前
14秒前
XiaoJiang完成签到,获得积分10
15秒前
852的应助被鲤鱼鑫磊采纳,获得10
15秒前
汉堡包的应助被Xk采纳,获得10
16秒前
Akim的应助被Xk采纳,获得10
16秒前
16秒前
17秒前
17秒前
NexusExplorer的应助被现代的代丝采纳,获得10
18秒前
闪闪兰发布了新的文献求助10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187362
求助须知:如何正确求助?哪些是违规求助? 9575478
关于积分的说明 21841431
捐赠科研通 7785067
什么是DOI,文献DOI怎么找? 3434943
关于科研通互助平台的介绍 2559401
邀请新用户注册赠送积分活动 2481820